Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q3 FY2019 Earnings Presentation
20 slides from Thyrocare Technologies's earnings presentation, Feb 9, 2019
Slide 1: Thyrocare
Thyrocare Think Thyroid. Think Thyrocare. February 11,2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Quarterly Res
Slide 2: Thyrocare Technologies Limited Q3-FY19 Presentation
Thyrocare Technologies Limited Q3-FY19 Presentation February 09, 2019
Slide 3: Disclaimer
Disclaimer • This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informat
Slide 4: Consolidated Financials Q3-FY19 Highlights
Consolidated Financials Q3-FY19 Highlights
Slide 5: Key Highlights – Q3-FY19 (YOY)
Key Highlights – Q3-FY19 (YOY) Consolidated : • Consolidated Revenue Of ₹ 96.29 Crores, ▲ 15% • Consolidated adjusted EBITDA Of ₹ 36.01 Crores (adjusted for one-offs like buyback expenses and CSR expenses) • Consolidated Profit before tax of ₹ 31.99 Crore Thyrocare Standalone: • Revenues Of ₹ 88
Slide 6: Consolidated Financials
Consolidated Financials Thyrocare [Consolidated] (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Nine Months Ended Nine 31 December 30 September 31 December (%) 31 December 31 December Month 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 96.29 103.88 83.87 15 297.
Slide 7: Thyrocare Standalone
Thyrocare Standalone Thyrocare’
Slide 8: Standalone Financials - Thyrocare
Standalone Financials - Thyrocare Thyrocare (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Nine Months Ended Nine 31 December 30 September 31 December (%) 31 December 31 December Month 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 88.12 95.68 77.84 13 272.99 241
Slide 9: Commentary on Financials - Thyrocare
Commentary on Financials - Thyrocare • Revenue from operations for the current quarter YOY has grown by 13 %. B2C revenue for the current quarter YOY ▲ 31 % [constitutes 21% (18%) of total revenue]. Revenue from preventive care tests, profiles & packages constitutes 55 % (47%) of the revenue from di
Slide 10: Key Financial Trends - Thyrocare
Key Financial Trends - Thyrocare Revenue (INR Cr) 95.7 90.0 89.2 88.1 82.4 82.1 81.8 77.8 73.4 64.5 65.7 Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 Q2-FY19 Q3-FY19 45. 0 EBITDA (Cr) 40.8 100 % 39.2 40. 0 35.8 33.9 33.8 35.3 34.0 90% 31.2 80% 29.9 35. 0 26.1 70% 30. 0 26.
Slide 11: Samples and Investigations
Samples and Investigations # Samples (‘000 Samples) # Investigations (‘000 investigations) 300 00 6 26,169.9 5.4 5.3 5.5 4,940.2 250 00 23,424.4 5.3 23,814.7 4,580.1 5.2 23,059.7 5.1 4,373.2 5.1 5.1 4,355.1 5 20,749.1 20,751.1 4,017.7 4,082.4 19,710.0 3,873.2 200 00 4.5 150 00 4 3.5 100 00 3 500 0 2
Slide 12: Key Operating Metrics – Business Lines
Key Operating Metrics – Business Lines Revenue Breakup (INR Cr) Volume Breakup (‘000 Samples) Q3-FY19 46.1 38.1 Q3-FY19 740.5 3,632.7 Q2-FY19 49.7 41.7 Q2-FY19 692.2 4,247.9 Q1-FY19 44.1 39.6 Q1-FY19 556.1 4,024.0 Q4-FY18 41.0 42.4 Q4-FY18 516.9 3,838.2 Q3-FY18 33.9 38.5 Q3-FY18 427.9 3,445.3 Q2-FY1
Slide 13: Key Operating Metrics – Regional Breakup
Key Operating Metrics – Regional Breakup Value Breakup (INR Cr) Volume Breakup (Lakh Samples) Q3-FY19 17.8 23.5 26.9 15.5 0.8 Q3FY19 8.8 13.5 11.2 10.2 0.1 Q2-FY19 20.0 23.1 29.8 17.9 0.6 Q2FY19 10.5 13.8 12.6 12.4 0.1 Q1-FY19 19.0 21.1 26.3 16.6 0.7 Q1FY19 10.0 12.5 11.6 11.6 0.1 Q4-FY18 13.4 20.1
Slide 14: Nueclear Standalone
Nueclear Standalone Nueclear
Slide 15: Standalone Financials - Nueclear
Standalone Financials - Nueclear Nueclear (Rs. in crore, except per share data) Particulars Quarter Endded Qtr. YOY Nine Months Ended Nine 31 December 30 September 31 December (%) 31 December 31 December Month 2018 2018 2017 2018 2017 YOY (%) Revenue from operations 8.16 8.19 6.03 35 24.31 17.90 36
Slide 16: Key Highlights – Nueclear – Q1-FY19
Key Highlights – Nueclear – Q1-FY19 • Nueclear has completed 90,827 PETCT scans as of December 31, 2018, since inception. • Nueclear has commenced operations at Bangalore PETCT and Coimbatore PETCT too, thus Nueclear has presently 12 locations covered by PETCT network. • Revenue from operations curr
Slide 17: Key Financial Trends - Nueclear
Key Financial Trends - Nueclear Revenue (INR Lakhs) 819.0 816.0 796.0 662.3 625.0 603.2 561.7 474.2 468.4 475.5 422.8 Q1-FY17 Q2-FY17 Q3-FY17 Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 Q2-FY19 Q3-FY19 200 .0 50% 179.2 189.0 180 .0 EBITDA (INR Lakhs) 156.4 45% 154.1 140.0 160 .0 40% 119.0 140 .0
Slide 18: Centerwise Scan Volumes
Centerwise Scan Volumes* 100% 629 933 90% 1,328 1,288 2,114 80% 3644 3,958 4,374 70% 60% 50% 4,166 4,782 40% 4,414 4,204 4,338 30% 4204 3,937 3,697 20% 10% 0% Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 Q2-FY19 Q3-FY19 Company operated Partner operated *Scan volumes include CT scans
Slide 19: Centerwise Scan Revenues
Centerwise Scan Revenues 100% 66.0 98.0 90% 145.8 145.5 171.8 80% 361.5 362.2 414.5 70% 60% 50% 371.0 437.0 40% 445.0 418.1 415.1 30% 398.6 361.2 338.3 20% 10% 0% Q4-FY17 Q1-FY18 Q2-FY18 Q3-FY18 Q4-FY18 Q1-FY19 Q2-FY19 Q3-FY19 Company operated Partner operated
Slide 20: Thank You
Thank You O Think Thyroid. Think Thyrocare. Nue clear NATIONWIDE NETWORKED
Thyrocare Technologies — Q3 FY2019 Earnings Presentation on 6ix